These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 11520837)

  • 61. Women's opinions and the implications of first- versus second-trimester screening for fetal Down's syndrome.
    Kornman LH; Wortelboer MJ; Beekhuis JR; Morssink LP; Mantingh A
    Prenat Diagn; 1997 Nov; 17(11):1011-8. PubMed ID: 9399348
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Fetal chromosomal abnormalities: antenatal screening and diagnosis.
    Anderson CL; Brown CE
    Am Fam Physician; 2009 Jan; 79(2):117-23. PubMed ID: 19178062
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Prenatal screening for Down syndrome in Australia: costs and benefits of current and novel screening strategies.
    O'Leary P; Maxwell S; Murch A; Hendrie D
    Aust N Z J Obstet Gynaecol; 2013 Oct; 53(5):425-33. PubMed ID: 24090461
    [TBL] [Abstract][Full Text] [Related]  

  • 64. First trimester nuchal translucency: effective routine screening for Down's syndrome.
    Thilaganathan B; Sairam S; Michailidis G; Wathen NC
    Br J Radiol; 1999 Oct; 72(862):946-8. PubMed ID: 10673944
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Ultrasound screening for Down's syndrome early in pregnancy: nuchal translucency thickness].
    Müller MA; Pajkrt E; Bilardo CM
    Ned Tijdschr Geneeskd; 2002 Apr; 146(17):793-8. PubMed ID: 12014236
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Applicability of first-trimester combined screening for fetal trisomy 21 in a resource-limited setting in mainland China.
    Li B; Sahota DS; Lao TT; Xu J; Hu SQ; Zhang L; Liu QY; Sun Q; Tang D; Ma RM
    BJOG; 2016 Sep; 123 Suppl 3():23-9. PubMed ID: 27627592
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Gradual implementation of first trimester screening in a population with a prior screening strategy: population based cohort study.
    Calda P; Sípek A; Gregor V
    Acta Obstet Gynecol Scand; 2010 Aug; 89(8):1029-33. PubMed ID: 20524903
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A cost-effectiveness analysis of amniocentesis and chorionic villus sampling for prenatal genetic testing.
    Heckerling PS; Verp MS
    Med Care; 1994 Aug; 32(8):863-80. PubMed ID: 8057700
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The value of screening for Down's syndrome in a socioeconomically deprived area with a high ethnic population.
    Ford C; Moore AJ; Jordan PA; Bartlett WA; Wyldes MP; Jones AF; MacKenzie WE
    Br J Obstet Gynaecol; 1998 Aug; 105(8):855-9. PubMed ID: 9746377
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Prenatal genetic diagnosis of Down's syndrome.
    Abbott MA; Benn P
    Expert Rev Mol Diagn; 2002 Nov; 2(6):605-15. PubMed ID: 12465456
    [TBL] [Abstract][Full Text] [Related]  

  • 71. An outcomes analysis of five prenatal screening strategies for trisomy 21 in women younger than 35 years.
    Biggio JR; Morris TC; Owen J; Stringer JS
    Am J Obstet Gynecol; 2004 Mar; 190(3):721-9. PubMed ID: 15042005
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Second trimester maternal serum screening for Down's syndrome in women of advanced maternal age: a multi-center prospective study].
    Qi QW; Jiang YL; Liu JT; Bian XM; Li Y; Lü SM; Zhu BS; Wang H; Xu ZF; Pan XY; Cai Y
    Zhonghua Fu Chan Ke Za Zhi; 2008 Oct; 43(10):737-41. PubMed ID: 19087538
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Prenatal diagnosis versus first-trimester screening of trisomy 21 among pregnant women aged 35 or more.
    Ghi T; Arcangeli T; Ravennati F; Salsi G; Montaguti E; Pacella G; Maroni E; Pittalis MC; Pompilii E; Pilu G; Rizzo N
    J Matern Fetal Neonatal Med; 2015 Apr; 28(6):674-8. PubMed ID: 24866349
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Model-based analysis of costs and outcomes of non-invasive prenatal testing for Down's syndrome using cell free fetal DNA in the UK National Health Service.
    Morris S; Karlsen S; Chung N; Hill M; Chitty LS
    PLoS One; 2014; 9(4):e93559. PubMed ID: 24714162
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Cost-benefit analysis of prenatal screening for trisomy 21 through analysis of HCG in maternal blood].
    Seror V; Moatti JP; Muller F; Le Galès C; Boué A
    Rev Epidemiol Sante Publique; 1993; 41(1):3-15. PubMed ID: 8465062
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Effects, safety and cost-benefit analysis of Down syndrome screening in first trimester].
    Shengmou L; Min C; Chenhong W; Shengli L; Jiansheng X; Hui Y; Dinghao L; Xiaoxia W; Wei W; Hongyun Z; Haiyan T
    Zhonghua Fu Chan Ke Za Zhi; 2014 May; 49(5):325-30. PubMed ID: 25030727
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Screening by maternal serum markers for Down's syndrome].
    Liu JT; Hao N; Sun NH; Wang FY; Xu YH; Gai MY; Bian XM; Yang JQ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Apr; 25(2):156-9. PubMed ID: 12905710
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [The development of screening tests for Down syndrome and the application of these tests in the Israeli health system].
    Weiner Z; Buda I; Halberthal M
    Harefuah; 2013 Sep; 152(9):543-6, 563. PubMed ID: 24364096
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Routinisation and constraints on informed choice in a one-stop clinic offering first trimester chromosomal antenatal screening for Down's syndrome.
    Tsouroufli M
    Midwifery; 2011 Aug; 27(4):431-6. PubMed ID: 20947230
    [TBL] [Abstract][Full Text] [Related]  

  • 80. First trimester screening for fetal abnormalities.
    Hyett J; Thilaganathan B
    Curr Opin Obstet Gynecol; 1999 Dec; 11(6):563-9. PubMed ID: 10674833
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.